Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients by Novick, Diego et al.
© 2016 Novick et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Neuropsychiatric Disease and Treatment 2016:12 795–800
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
795
O r i g i N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/NDT.S90134
impact of anxiety symptoms on outcomes of 
depression: an observational study in asian 
patients
Diego Novick1
William Montgomery2
Jaume aguado3
Xiaomei Peng4
Josep Maria haro3
1eli lilly and company, Windlesham, 
surrey, UK; 2eli lilly australia Pty ltd, 
West ryde, NsW, australia; 3Parc  
sanitari sant Joan de Déu, ciBersaM,  
Universitat de Barcelona, Barcelona,  
spain; 4eli lilly and company, 
indianapolis, iN, Usa
Objective: To investigate the impact of anxiety symptoms on depression outcomes in Asian 
patients with major depressive disorder (MDD) (n=714).
Methods: The 17-item Hamilton Depression Scale (HAMD-17), overall severity, somatic symp-
toms, and quality of life (QOL) (EuroQOL Questionnaire-5 Dimensions [EQ-5D]) were assessed 
at baseline and 3 months. Anxiety was measured using items 10 and 11 from the HAMD-17. 
Linear, tobit, and logistic multiple regression models analyzed the impact of anxiety symptoms on 
outcomes. Baseline anxiety was related to age and the presence of pain symptoms at baseline.
Results: Regression models showed that a higher level of anxiety was associated with a lower 
frequency of remission and lower QOL at 3 months. Patients with lower baseline anxiety symp-
toms had higher remission rates (odds ratio for each point of anxiety symptoms, 0.829 [95% 
confidence interval [CI]: 0.723–0.951]). Patients with higher levels of baseline anxiety had a 
lower QOL at 3 months (a decrease in EQ-5D tariff score for each point of anxiety symptoms, 
0.023 [95% CI: 0.045–0.001]).
Conclusion: In conclusion, the presence of anxiety symptoms negatively impacts the outcomes 
of depression.
Keywords: depression, anxiety, Asia, observational, outcomes
Introduction
Anxiety and depressive disorders are highly comorbid.1–4 In an analysis of data from 
the World Health Organization (WHO) World Mental Health surveys (a series of large 
community epidemiological surveys conducted in ten developed and eight develop-
ing countries), for example, all 14 of the 12-month DSM-IV disorders – including 
anxiety disorders – were significantly and positively associated with 12-month major 
depressive episodes.2 In his review of depression and anxiety, Tiller4 concluded that 
approximately 85% of patients with depression have significant anxiety and that 90% 
of patients with anxiety disorder have depression.
The presence of anxiety symptoms in individuals with major depressive disorder 
(MDD) has long been proposed as an indicator of poor treatment response and a 
worse prognosis.5 Findings, however, have been mixed; some studies report that 
response rates in patients with anxious depression were not significantly lower than 
response rates in those with nonanxious depression,6–8 while other studies found 
treatment to be less effective in patients with anxious depression compared with those 
with nonanxious depression.9–11 More recently, the debate was rekindled by findings 
from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 
in which patients with anxious depression were found to be less likely to respond to 
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and achieve remission following antidepressant treatment 
compared with those with nonanxious depression.5 Once 
again, however, findings from subsequent studies and 
analyses continue to suggest that anxiety is not a strong 
predictor of the treatment outcome of depression,12,13 and so 
the debate continues.14
Pain further complicates the clinical picture. An associa-
tion has been reported between pain and depression, as well 
as between pain and anxiety.15 Pain is often found alongside 
anxiety and depression in primary care patients,16,17 and the 
three phenomena may exhibit different relationships over 
time.18 Pain, like anxiety, has been proposed as a predictor 
of poor outcomes in depression; depressed patients with 
pain have been reported to have lower response rates19 and 
lower quality of life (QOL) outcomes20 compared with those 
without pain.
Much of the research into anxious depression, however, 
has been conducted in European and US populations, and 
there is little information available from Asian countries.21 
The objective of this analysis was to assess the influence 
of anxiety symptoms on outcomes in Asian patients with 
MDD, taking into account the presence of painful physical 
symptoms (PPS). We also evaluated the interaction between 
anxiety symptoms and pain.
Materials and methods
study design and population
Data for this post hoc analysis were taken from a prospec-
tive, noninterventional observational study designed to 
assess the frequency of somatic symptoms in East Asian 
patients treated for an acute episode of a MDD in psychiatric 
care settings.22 The study enrolled patients from 30 study 
sites across six East Asian countries and regions: People’s 
Republic of China, Hong Kong, Korea, Malaysia, Singapore, 
and Taiwan. Patients were recruited from June 14, 2006 to 
February 15, 2007, with patients assessed at baseline and at 
3 months after treatment.
Patients eligible for inclusion in the study were inpatients 
or outpatients, at least 18 years of age, who presented with a 
new or first episode of MDD, as defined by the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition 
Text Revision23 or International Classification of Diseases, 
Tenth Revision.24 In addition, patients also had to have a 
Clinical Global Impression-Severity of Illness (CGI-S)25 
score of $4 (moderate) at study entry, at least 2 months 
free of depression symptoms prior to the onset of the present 
episode, and consent to participate. Patients were excluded 
if their current depressive episode had persisted for more 
than 6 continuous months; if they had a previous or current 
diagnosis of schizophrenia, schizophreniform disorder, 
schizoaffective disorder, bipolar disorder, or dementia; 
were experiencing chronic treatment-resistant pain or pain 
of an inflammatory origin related to an identified medical 
condition; or if they were simultaneously participating in 
another study that included a treatment intervention or an 
investigational drug.
There were neither restrictions nor recommendations 
regarding treatment; all treatment decisions were based 
solely on the clinician’s usual practice in the provision of 
care to patients with MDD. Adverse events were reported to 
the appropriate authority according to each country’s local 
rules, regulations, and legislation. The study was conducted 
in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki and that are consistent 
with the International Conference on Harmonization good 
clinical practice guidelines. The study was approved by the 
institutional or ethical review board of at least one site in each 
participating country or region. Written informed consent 
was obtained from all patients or their legal representative 
prior to enrollment.22
Measures
Demographic and clinical data were collected at the baseline 
visit. Overall disease severity, and depression and anxiety 
severity were assessed at baseline and 3 months after 
treatment. The severity of depression was measured using the 
17-item Hamilton Rating Scale for Depression (HAMD-17);26 
this measure includes anxiety symptoms. Anxiety symptoms 
were measured separately using items 10 and 11 from the 
HAMD-17, in which anxiety is rated on a scale from 0 to 8, 
with higher anxiety scores indicating increasing severity 
of anxiety. The modified 15-item Hamilton Rating Scale 
(HAMD-15) excludes anxiety items 10 and 11 and so 
assesses the severity of depression without anxiety. Overall 
disease severity was assessed using the CGI-S.
The presence and absence of PPS (PPS+ and PPS-) was 
defined as a mean score of $2 on the pain-related items of 
the Somatic Symptom Inventory (SSI).27 The SSI is a 28-item, 
patient self-report scale that assesses the extent to which 
each of 28 somatic symptoms bothered the patient over the 
previous week, using a scale ranging from 1 (“not at all”) 
to 5 (“a great deal”); the pain-related items are abdominal, 
lower back, joint, neck, heart and chest pain, headache, and 
muscular soreness.
QOL and health status were assessed using the EuroQOL 
Questionnaire-5 Dimensions (EQ-5D).28 This is a self-rated, 
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generic, health-related QOL instrument consisting of two 
parts; five questions on general health covering the dimen-
sions of mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression (EQ-5D); and a visual analog 
scale (VAS) that patients use to assess their current level of 
health on the day of scoring from 0 (worst imaginable health 
state) to 100 (best imaginable health state) (EQ-VAS). The 
five questions on general health were translated into QOL 
tariff scores using the available UK population tariffs.29
Remission was defined as a HAMD-17 total score of #7 
at 3 months.
statistical analysis
The association between anxiety symptoms at baseline and 
the outcomes of depression was analyzed using regres-
sion models. Multiple linear regression was used for the 
HAMD-15 and HAMD-17 scores, the CGI, and the EQ-5D 
VAS. Tobit regression was used for EQ-5D score to account 
for the ceiling effect at 1 (43% of the sample). Logistic 
regression was used for remission.
All models were adjusted for age, sex, PPS status, 
country, the baseline value of the outcome variable, and any 
other variable associated to the outcome (P,0.10) in the 
descriptive analysis; the variables that were tested were as 
follows: previous MDD episodes, hospitalizations, marital 
status, employment, living arrangements, cardiovascular 
disease, CGI, HAMD-15, pain intensity, SSI total score, 
EQ-5D VAS, and tariff. In all models, the interaction term 
anxiety–PPS was tested.
All statistical analyses were performed using SAS© version 
9.2 for Windows™ (SAS Institute, Cary, NC, USA).
Results
A total of 917 patients were recruited; eight had missing SSI 
data and so were excluded, leaving 909 patients enrolled 
in the study. Of these 909 patients, 714 (79%) had both 
baseline and 3-month assessments and were included in this 
analysis. Of the analysis population, 69% of patients were 
women, 45% had previous MDD episodes, and 49% had 
PPS (PPS+) at baseline. Mean age at the baseline visit was 
45.90 (standard deviation [SD]: 14.18) years, mean CGI-S 
score was 4.79 (SD: 0.74), and HAMD-17 total score was 
23.56 (SD: 5.72).
Analysis of anxiety symptom scores by patient charac-
teristics at baseline is summarized in Table 1. There was a 
significant difference in anxiety symptoms by PPS status 
at baseline; patients who were PPS+ had a higher anxiety 
score than those who were PPS- (P,0.001). There were also 
age differences in anxiety ratings, with increasing anxiety 
ratings with age. There were no significant differences in 
anxiety symptom scores between any of the other baseline 
patient characteristic categories (ie, sex, marital status, 
employment status, previous MDD episodes, and number 
of comorbidities).
Analysis of anxiety scores at baseline and the severity 
of depression and QOL at baseline and at 3 months revealed 
that the correlation between anxiety was significant both 
at baseline and at 3 months (all P,0.0001; Table 2). 
This finding indicates that anxiety at baseline is related 
to severity of depression (HAMD-17 and HAMD-15), 
overall severity (CGI-S), and QOL at baseline, and that 
anxiety at baseline is also related to the same outcomes 
at 3 months.
The regression models analyzed the relationship 
between baseline anxiety and outcome variables, taking into 
account the presence of other baseline predictors (including 
HAMD-15, PPS, age, sex, country, hospitalization, marital 
status, living conditions, work, and comorbidities; Table 3). 
Table 1 anxiety symptom score by baseline patient characteristics
Baseline 
characteristic
Number 
of patients
Anxiety 
symptom score, 
mean (SD)
P-value
sex 0.8445
Female 493 3.81 (1.46)
Male 221 3.83 (1.47)
age, years 0.0142
,40 221 3.58 (1.49)
$40 to ,60 373 3.90 (1.42)
$60 120 3.99 (1.50)
Marital status 0.2706
Married/de facto 
spouse
494 3.86 (1.49)
single 108 3.61 (1.50)
Divorced/widowed/ 
separated
112 3.81 (1.30)
employment status (part-/full-time work) 0.2511
No 421 3.87 (1.45)
Yes 291 3.74 (1.48)
Previous MDD episode 0.2897
No 385 3.88 (1.47)
Yes 313 3.76 (1.46)
PPs status ,0.001
PPs- 361 3.48 (1.43)
PPs+ 353 4.16 (1.42)
Number of comorbidities 0.3366
None 534 3.78 (1.45)
1 130 3.98 (1.57)
.1 45 3.89 (1.19)
Abbreviations: MDD, major depressive disorder; PPs, painful physical symptoms; 
sD, standard deviation. 
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Patients with higher levels of baseline anxiety symptoms had 
lower remission rates (odds ratio [OR] of remission for each 
point of anxiety symptoms, 0.829 [95% CI: 0.723–0.951]). 
Patients with higher levels of baseline anxiety symptoms had 
a lower level of QOL at 3 months (decrease in EQ-5D VAS 
score for each point of anxiety symptoms, 0.955 [95% CI: 
0.093–2.003]). In the models analyzing the impact of anxiety 
symptoms overall severity (CGI-S), HAMD-15 and EQ-5D 
scores showed that the presence of anxiety was associated 
with worse outcomes, but this association did not reach 
statistical significance when adjusting for other covariates. 
In all of the models, pain (PPS+ status) was highly predictive 
of poor outcomes. The interaction of anxiety and PPS+ was 
not significant in any of the models.
Discussion
The main findings of this study were that anxiety symptoms 
in Asian MDD patients are associated with worse remission 
and QOL (EQ-5D tariff score) at 3 months. These findings 
were maintained in the regression model when adjusting 
for other covariates. The relationship between anxiety, 
depression, and QOL outcomes was strong in the descriptive 
analysis, but was weaker when adjusted for the presence of 
other covariates, particularly pain status. Our findings also 
indicate that pain is a significant predictor of poor outcome 
and that anxiety and pain are related.
As findings in the literature are mixed, the findings of this 
analysis conflict with some studies and agree with others. 
Specifically, the findings of our analysis conflict with the 
large amount of data from placebo-controlled clinical trials 
of antidepressants, and a number of analyses that suggest that 
anxiety is not a strong predictor of the treatment outcome 
of depression, that response rates in patients with anxious 
depression were not significantly lower than response rates 
in those with nonanxious depression, and that drug–placebo 
differences did not differ between the two groups.6–8,12–14 
In contrast, our findings are in line with a modest amount of 
data from a smaller number of open-label and naturalistic 
studies that reported the presence of anxiety symptoms in 
individuals with MDD to be an indicator of poor treatment 
response and a worse prognosis.5,9–11
There is currently no universally accepted definition 
of anxious depression;14 the WHO is revising the primary 
health care classification of mental and behavioral disorders 
to accommodate this condition.30 It is possible that different 
results relating to anxious depression outcomes are being 
reported by different studies because they are assessing subtly 
different patient populations, and using different measures to 
assess anxiety symptoms within these populations. This study 
focused on MDD patients with anxiety symptoms and used a 
modified version of the HAMD-17 to do this. In the STAR*D 
study, anxious depression was defined as MDD with high 
levels of anxiety symptoms based on a different modifica-
tion of the HAMD-17 scale.5 The Clinical Research Center 
for Depression (CRESCEND) study specifically excluded 
comorbid anxiety disorder from their anxious depression 
population, and used a Hamilton Anxiety Scale total score 
of $20 to define anxious depression.14,31 Further work is 
required to optimize the identification of anxious depression 
as a clinically significant subtype of depression, and as an aid 
to tailoring treatment for individual MDD patients.14
Differing effects among antidepressant drugs have been 
reported,32 and it is possible that the selection of antidepressants 
with anxiolytic effects may lead to improved depression out-
comes in patients with anxious depression. Studies that have 
not found anxiety symptoms to predict poorer depression 
outcomes may have used different antidepressants with 
Table 2 correlation between anxiety score at baseline and 
severity of depression and QOl at baseline and at 3 months
Parameter Pearson correlation P-value
Baseline
cgi-s score 0.326 ,0.0001
haMD-17 total score 0.659 ,0.0001
haMD-15 total scorea 0.473 ,0.0001
eQ-5D tariff score -0.334 ,0.0001
eQ-5D Vas score -0.197 ,0.0001
3 months
cgi-s score 0.142 0.0001
haMD-17 total score 0.20 ,0.0001
haMD-15 total scorea 0.162 ,0.0001
eQ-5D tariff score -0.16 ,0.0001
eQ-5D Vas score -0.123 0.001
Note: ahaMD-15 includes all but anxiety symptoms of haMD-17.
Abbreviations: cgi-s, clinical global impression-severity; eQ-5D, euroQOl 
Questionnaire-5 Dimensions; haMD, hamilton Depression rating scale; QOl, 
quality of life; Vas, visual analog scale.
Table 3 effect of anxiety on outcomes at 3 months (linear and 
logistic regression models)
Outcomes Effect of anxiety  
symptomsa
95% CI
cgi-s score 0.049 -0.010 to 0.109
haMD-15 total score 0.194 -0.085 to 0.474
eQ-5D Vas score -0.955 -2.003 to 0.093
eQ-5D tariff score -0.023 -0.045 to -0.001
Anxiety ORb 95% CI
remission 0.829 0.723 to 0.951
Notes: aRegression coefficient obtained with multiple linear regression, except for 
the eQ-5D tariff where tobit regression was used. bOr from logistic regression.
Abbreviations: cgi-s, clinical global impression-severity; eQ-5D, euroQOl 
Questionnaire-5 Dimensions; haMD, hamilton Depression rating scale; Vas, visual 
analog scale; OR, odds ratio; QOL, quality of life; CI, confidence interval.
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anxiolytic effects.14 It has also been suggested that the use 
of fixed treatment modalities, as occurred in the STAR*D 
study5 rather than a broader treatment (flexible treatment 
plus the allowance of concomitant medications including 
anxiolytics/hypnotics and antipsychotics) as used in the 
CRESCEND study,14 might account for different findings 
between studies. This analysis did not take into account the 
antidepressant prescribed, or the treatment modality (broad 
and flexible versus fixed), which might have influenced 
outcomes.
The findings from this study indicate that anxiety and pain 
are related. This finding is in line with those from the study 
conducted by Means-Christensen et al15 in which an associa-
tion was reported not only between pain and depression, but 
also between pain and anxiety; patients with an anxiety or 
depressive disorder reported greater interference from pain, 
while patients with pain symptoms reported lower mental 
health functioning and more severe depression and anxiety 
disorders. Anxiety, depression, and pain appear to share simi-
lar pathophysiological mechanisms,33,34 and a neurochemical 
pathway that is influenced by serotonin.35,36 However, the 
association between these phenomena is complex, underly-
ing mechanisms are not yet fully understood, and the specific 
interrelationships remain unclear.
While the relationships between anxiety symptoms and 
pain in MDD remain obscure, the clinical implications of 
these findings seem clear – that clinicians need to take into 
account the presence of both anxiety and pain when treating 
patients with depression.
Limitations
Some limitations should be considered when interpreting 
the results of this analysis. Given the observational design 
of the study from which the data are drawn, our findings 
should be interpreted conservatively. The presence of anxiety 
symptoms in our MDD patients was assessed using two items 
of the HAMD and not with a specific scale. Only patients 
from psychiatric care settings and no patients from primary 
care were included, which means that our patient sample is 
not representative of the whole MDD population in these 
Asian countries and thus limits the generalizability of our 
findings to primary care patients with MDD. As mentioned 
previously, this analysis did not take into account the anti-
depressant prescribed, which may influence outcomes at 
3 months. Furthermore, the use of pain relief medication was 
not assessed. Finally, as there is no Asian EQ-5D tariff, we 
applied the commonly used UK tariff to the EQ-5D data of 
the Asian patients to calculate the utility scores.28 While there 
is evidence that different populations (including different 
racial/ethnic populations) value health states differently,37–39 
the EQ-5D has been shown to be useful for assessing QOL 
in patients with MDD40 and to have acceptable validity 
and reliability in Asian populations.41 In addition, both the 
EQ-VAS and the EQ-5D utility scores have been shown to 
be responsive to change in patients with depression.42
Conclusion
The presence of anxiety symptoms in Asian MDD patients 
negatively impacts remission status and QOL, indicating that 
anxiety symptoms should be taken into account when tailor-
ing therapy for individual patents. It is important to note that 
pain and anxiety symptoms are also related. Further studies 
are needed to understand the relationships between pain and 
anxiety symptoms in MDD patients.
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